Skip to main content
Article thumbnail
Location of Repository

The MiRNA Journey from Theory to Practice as a CNS Biomarker

By Nicoleta eStoicea, Amy eDu, Dorothy eLakis, Courtney eTipton, Carlos E Arias Morales and Sergio Daniel Bergese and Sergio Daniel Bergese


MicroRNAs (miRNAs), small nucleotide sequences that control gene transcription, have the potential to serve an expanded function as indicators in the diagnosis and progression of neurological disorders. Studies involving debilitating neurological diseases such as, Alzheimer’s disease, multiple sclerosis, traumatic brain injuries, Parkinson’s disease and CNS tumors, already provide validation for their clinical diagnostic use. These small nucleotide sequences have several features, making them favorable candidates as biomarkers, including function in multiple tissues, stability in bodily fluids, a role in pathogenesis, and the ability to be detected early in the disease course. Cerebrospinal fluid, with its cell-free environment, collection process that minimizes tissue damage, and direct contact with the brain and spinal cord, is a promising source of miRNA in the diagnosis of many neurological disorders. Despite the advantages of miRNA analysis, current analytic technology is not yet affordable as a clinically viable diagnostic tool and requires standardization. The goal of this review is to explore the prospective use of CSF miRNA as a reliable and affordable biomarker for different neurological disorders

Topics: neurodegenerative disease, biomarker, MicroRNA (miRNA), cerebrospinal fluid (CSF), central nervous system (CNS), Genetics, QH426-470
Publisher: Frontiers Media S.A.
Year: 2016
DOI identifier: 10.3389/fgene.2016.00011
OAI identifier:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • (external link)
  • (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.